SCHEMBL1967100

SCHEMBL1967100

COc1nccnc1NS(=O)(=O)c1cccc(Cl)c1F

nearest known ligand 0.77

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 18/20 0.77
SLC40A1 Q9NP59 1/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29369177 0.87 CCR4 (1.00) CCR4
SCHEMBL1731222 0.87 CCR4 (1.00) CCR4
SCHEMBL1733302 0.85 CCR4 (0.77) CCR4MEN1KMT2A
SCHEMBL1733142 0.84 CCR4 (1.00) CCR4
SCHEMBL1968579 0.84 CCR4 (0.83) CCR4
SCHEMBL1970693 0.82 CCR4 (0.80) CCR4
SCHEMBL1732073 0.81 CCR4 (0.79) CCR4MEN1KMT2A
SCHEMBL1732411 0.80 CCR4 (0.69) CCR4MEN1KMT2A
SCHEMBL1968930 0.79 CCR4 (0.74) CCR4
SCHEMBL1733196 0.79 CCR4 (0.65) CCR4SLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968951-B1 NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMID.ES AS MOODULATORS OF CHEMOKINE RECEPTOR CCR4. ASTRAZENECA AB (SE) 2011-06-22 EP disclosed
EP-1968951-B1 NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMID.ES AS MOODULATORS OF CHEMOKINE RECEPTOR CCR4. ASTRAZENECA AB (SE) 2011-06-22 EP disclosed
US-20100144759-A1 NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMIDES AS MODULATORS OF CHEMOKINE RECEPTOR CCR4 ASTRAZENECA AB (SE) 2010-06-10 US disclosed
US-20100144759-A1 NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMIDES AS MODULATORS OF CHEMOKINE RECEPTOR CCR4 ASTRAZENECA AB (SE) 2010-06-10 US disclosed
US-20100144759-A1 NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMIDES AS MODULATORS OF CHEMOKINE RECEPTOR CCR4 ASTRAZENECA AB (SE) 2010-06-10 US disclosed
US-20080293742-A1 Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of Chemokine Receptor Ccr4 ASTRAZENECA AB (SE) 2008-11-27 US disclosed
US-20080293742-A1 Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of Chemokine Receptor Ccr4 ASTRAZENECA AB (SE) 2008-11-27 US disclosed
US-20080293742-A1 Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of Chemokine Receptor Ccr4 ASTRAZENECA AB (SE) 2008-11-27 US disclosed
EP-1968951-A1 NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMID.ES AS MOODULATORS OF CHEMOKINE RECEPTOR CCR4. AstraZeneca AB (SE) 2008-09-17 EP disclosed
WO-2007069978-A1 NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMID.ES AS MOODULATORS OF CHEMOKINE RECEPTOR CCR4. ASTRAZENECA AB (SE) 2007-06-21 WO disclosed
WO-2007069978-A1 NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMID.ES AS MOODULATORS OF CHEMOKINE RECEPTOR CCR4. ASTRAZENECA AB (SE) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293742-A1 Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of Chemokine Receptor Ccr4 CCR4, CCR1, CCR3 CCR4 1/4885SLC40A1 2315/4885MEN1 4643/4885
US-20100144759-A1 NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMIDES AS MODULATORS OF CHEMOKINE RECEPTOR CCR4 CCR4, CCR1, CCR3 CCR4 1/4885SLC40A1 2315/4885MEN1 4643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.